Scheduling of anticancer drugs

References

• Azmi AS, Banerjee S, Ali S, Wang Z, Bao B, Beck FW, et al. Network modeling of MDM2 inhibitor-oxaliplatin combination reveals biological synergy in wt-p53 solid tumors. Oncotarget 2011; 2:378 - 92; PMID: 21623005
   PubMed Web of Science ®Google Scholar
• Luchenko VL, Salcido CD, Zhang Y, Agama K, Komlodi-Pasztor E, Murphy RF, et al. Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer. Cell Cycle 2011; 10:3119 - 28; http://dx.doi.org/10.4161/cc.10.18.17190; PMID: 21900747
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al, TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125 - 34; http://dx.doi.org/10.1056/NEJMoa060655; PMID: 17215530
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335 - 42; http://dx.doi.org/10.1056/NEJMoa032691; PMID: 15175435
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666 - 76; http://dx.doi.org/10.1056/NEJMoa072113; PMID: 18160686
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115 - 24; http://dx.doi.org/10.1056/NEJMoa065044; PMID: 17215529
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542 - 50; http://dx.doi.org/10.1056/NEJMoa061884; PMID: 17167137
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28:1061 - 8; http://dx.doi.org/10.1200/JCO.2009.23.9764; PMID: 20100962
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427 - 34; http://dx.doi.org/10.1056/NEJMoa021491; PMID: 12890841
   PubMed Web of Science ®Google Scholar
• Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6:389 - 95; http://dx.doi.org/10.1038/74651; PMID: 10742145
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57 - 70; http://dx.doi.org/10.1016/S0092-8674(00)81683-9; PMID: 10647931
   PubMed Web of Science ®Google Scholar
• Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438:967 - 74; http://dx.doi.org/10.1038/nature04483; PMID: 16355214
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669 - 76; http://dx.doi.org/10.1038/nm0603-669; PMID: 12778165
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3:391 - 400; http://dx.doi.org/10.1038/nrd1381; PMID: 15136787
   PubMed Web of Science ®Google Scholar
• Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009; 27:4966 - 72; http://dx.doi.org/10.1200/JCO.2008.21.6630; PMID: 19720913
   PubMed Web of Science ®Google Scholar
• www.fda.gov/downloads/NewsEvents/Newsroom/UCM280546.pdf .
   Google Scholar
• Montero AJ, Vogel C. Fighting fire with fire: rekindling the bevacizumab debate. N Engl J Med 2012; 366:374 - 5; http://dx.doi.org/10.1056/NEJMe1113368; PMID: 22276827
   PubMed Web of Science ®Google Scholar
• Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002; 2:683 - 93; http://dx.doi.org/10.1038/nrc882; PMID: 12209157
   PubMed Web of Science ®Google Scholar
• van der Veldt AA, Luurtsema G, Lubberink M, Lammertsma AA, Hendrikse NH. Individualized treatment planning in oncology: role of PET and radiolabelled anticancer drugs in predicting tumour resistance. Curr Pharm Des 2008; 14:2914 - 31; http://dx.doi.org/10.2174/138161208786404344; PMID: 18991710
   PubMed Web of Science ®Google Scholar
• Dimitrakopoulou-Strauss A, Strauss LG, Schlag P, Hohenberger P, Möhler M, Oberdorfer F, et al. Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma. J Nucl Med 1998; 39:1197 - 202; PMID: 9669393
   PubMed Web of Science ®Google Scholar
• Moehler M, Dimitrakopoulou-Strauss A, Gutzler F, Raeth U, Strauss LG, Stremmel W. 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. Cancer 1998; 83:245 - 53; http://dx.doi.org/10.1002/(SICI)1097-0142(19980715)83:2<245::AID-CNCR7>3.0.CO;2-P; PMID: 9669806
   PubMed Web of Science ®Google Scholar
• Inoue T, Kim EE, Wallace S, Yang DJ, Wong FC, Bassa P, et al. Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study. Cancer Biother Radiopharm 1996; 11:235 - 45; http://dx.doi.org/10.1089/cbr.1996.11.235; PMID: 10851543
   PubMed Web of Science ®Google Scholar
• van der Veldt AA, Lubberink M, Greuter HN, Comans EF, Herder GJ, Yaqub M, et al. Absolute quantification of [(11)C]docetaxel kinetics in lung cancer patients using positron emission tomography. Clin Cancer Res 2011; 17:4814 - 24; http://dx.doi.org/10.1158/1078-0432.CCR-10-2933; PMID: 21750197
   PubMed Web of Science ®Google Scholar
• Aboagye EO, Saleem A, Cunningham VJ, Osman S, Price PM. Extraction of 5-fluorouracil by tumor and liver: a noninvasive positron emission tomography study of patients with gastrointestinal cancer. Cancer Res 2001; 61:4937 - 41; PMID: 11431319
   PubMed Web of Science ®Google Scholar
• Bading JR, Alauddin MM, Fissekis JD, Shahinian AH, Joung J, Spector T, et al. Blocking catabolism with eniluracil enhances PET studies of 5-[18F]fluorouracil pharmacokinetics. J Nucl Med 2000; 41:1714 - 24; PMID: 11038003
   PubMed Web of Science ®Google Scholar
• Bading JR, Yoo PB, Fissekis JD, Alauddin MM, D’Argenio DZ, Conti PS. Kinetic modeling of 5-fluorouracil anabolism in colorectal adenocarcinoma: a positron emission tomography study in rats. Cancer Res 2003; 63:3667 - 74; PMID: 12839957
   PubMed Web of Science ®Google Scholar
• Saleem A, Yap J, Osman S, Brady F, Suttle B, Lucas SV, et al. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action. Lancet 2000; 355:2125 - 31; http://dx.doi.org/10.1016/S0140-6736(00)02380-1; PMID: 10902627
   PubMed Web of Science ®Google Scholar
• Gupta N, Saleem A, Kötz B, Osman S, Aboagye EO, Phillips R, et al. Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients. Clin Cancer Res 2006; 12:3115 - 23; http://dx.doi.org/10.1158/1078-0432.CCR-05-0513; PMID: 16707610
   PubMed Web of Science ®Google Scholar
• Harte RJ, Matthews JC, O’Reilly SM, Tilsley DW, Osman S, Brown G, et al. Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa. J Clin Oncol 1999; 17:1580 - 8; PMID: 10334547
   PubMed Web of Science ®Google Scholar
• Bomber P, McCready R, Hammersley P. Propranolol hydrochloride enhancement of tumor perfusion and uptake of gallium-67 in a mouse sarcoma. J Nucl Med 1986; 27:243 - 5; PMID: 3712042
   PubMed Web of Science ®Google Scholar
• Pasquier E, Ciccolini J, Carre M, Giacometti S, Fanciullino R, Pouchy C, et al. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget 2011; 2:797 - 809; PMID: 22006582
   PubMed Web of Science ®Google Scholar
• van der Veldt AA, Hendrikse NH, Harms HJ, Comans EF, Postmus PE, Smit EF, et al. Quantitative parametric perfusion images using 15O-labeled water and a clinical PET/CT scanner: test-retest variability in lung cancer. J Nucl Med 2010; 51:1684 - 90; http://dx.doi.org/10.2967/jnumed.110.079137; PMID: 20956480
   PubMed Web of Science ®Google Scholar
• Flower MA, Zweit J, Hall AD, Burke D, Davies MM, Dworkin MJ, et al. 62Cu-PTSM and PET used for the assessment of angiotensin II-induced blood flow changes in patients with colorectal liver metastases. Eur J Nucl Med 2001; 28:99 - 103; http://dx.doi.org/10.1007/s002590000410; PMID: 11202458
   PubMedGoogle Scholar
• Koh T, Taniguchi H, Yamagishi H. Oxygen-15 positron-emission tomography for predicting selective delivery of a chemotherapeutic agent to hepatic cancers during angiotensin II-induced hypertension. Cancer Chemother Pharmacol 2003; 51:349 - 58; PMID: 12721763
   PubMed Web of Science ®Google Scholar
• Taniguchi H, Koyama H, Masuyama M, Takada A, Mugitani T, Tanaka H, et al. Angiotensin-II-induced hypertension chemotherapy: evaluation of hepatic blood flow with oxygen-15 PET. J Nucl Med 1996; 37:1522 - 3; PMID: 8790207
   PubMed Web of Science ®Google Scholar
• Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 2012; 21:82 - 91; http://dx.doi.org/10.1016/j.ccr.2011.11.023; PMID: 22264790
   PubMed Web of Science ®Google Scholar
• Zissen MH, Kunz P, Subbarayan M, Chin FT, Conti PS, Fisher GA, et al. 18F-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases. Nucl Med Commun 2011; 32:343 - 7; http://dx.doi.org/10.1097/MNM.0b013e328344894b; PMID: 21412178
   PubMed Web of Science ®Google Scholar
• Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA 2012; 109:2784 - 9; http://dx.doi.org/10.1073/pnas.1018866109; PMID: 22308314
   PubMed Web of Science ®Google Scholar
• Conley SJ, Wicha MS. Antiangiogenic agents: fueling cancer’s hypoxic roots. Cell Cycle 2012; 11:1265 - 6; http://dx.doi.org/10.4161/cc.19890; PMID: 22421155
   PubMed Web of Science ®Google Scholar
• Casanovas O. Cancer: Limitations of therapies exposed. Nature 2012; 484:44 - 6; http://dx.doi.org/10.1038/484044a; PMID: 22481354
   PubMed Web of Science ®Google Scholar
• Shen DW, Fojo A, Chin JE, Roninson IB, Richert N, Pastan I, et al. Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification. Science 1986; 232:643 - 5; http://dx.doi.org/10.1126/science.3457471; PMID: 3457471
   PubMed Web of Science ®Google Scholar
• Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 1997; 40:Suppl S13 - 9; http://dx.doi.org/10.1007/s002800051055; PMID: 9272128
   PubMed Web of Science ®Google Scholar
• Lin JH. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev 2003; 55:53 - 81; http://dx.doi.org/10.1016/S0169-409X(02)00171-0; PMID: 12535574
   PubMed Web of Science ®Google Scholar
• Chan LM, Lowes S, Hirst BH. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 2004; 21:25 - 51; http://dx.doi.org/10.1016/j.ejps.2003.07.003; PMID: 14706810
   PubMed Web of Science ®Google Scholar
• van Zuylen L, Verweij J, Nooter K, Brouwer E, Stoter G, Sparreboom A. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res 2000; 6:2598 - 603; PMID: 10914699
   PubMed Web of Science ®Google Scholar
• Conti PS, Keppler JS, Halls JM. Positron emission tomography: a financial and operational analysis. AJR Am J Roentgenol 1994; 162:1279 - 86; PMID: 8191981
   PubMed Web of Science ®Google Scholar
• Keppler JS, Conti PS. A cost analysis of positron emission tomography. AJR Am J Roentgenol 2001; 177:31 - 40; PMID: 11418393
   PubMed Web of Science ®Google Scholar
• van der Veldt AA, Smit EF. Bevacizumab in neoadjuvant treatment for breast cancer. N Engl J Med 2012; 366:1637 - 40, author reply 1638-40; http://dx.doi.org/10.1056/NEJMc1202229; PMID: 22533581
   PubMed Web of Science ®Google Scholar
• Wang ES, Pili R, Seshadri M. Modulation of chemotherapeutic efficacy by vascular disrupting agents: optimizing the sequence and schedule. J Clin Oncol 2012; 30:760 - 1, author reply 761-3; http://dx.doi.org/10.1200/JCO.2011.39.3934; PMID: 22291088
   PubMed Web of Science ®Google Scholar